BLTE — BELITE BIO, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1889109 ·
Last close
$142.01
Market Cap
$5.69B
52W High
$192.28
52W Low
$134.01
ADV30
130,607
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -32,684,000 | -26,938,000 | 811,271,000 | — | 15,483,000 |
| Dec 2025 | 0 | — | -28,077,000 | -25,324,000 | 780,556,000 | 352,932,000 | 10,070,000 |
| Sep 2025 | 0 | — | -23,018,000 | -21,690,000 | 282,393,000 | 157,034,000 | 8,311,000 |
| Jun 2025 | 0 | — | -17,596,000 | -16,320,000 | 156,407,000 | — | 6,522,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,986,000
Investing CF
$-329,748,000
Financing CF
$549,893,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.30
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-185,258,000
Inventory
—
Receivables
$718,000
ST Investments
$139,490,000
EBIT TTM
$-77,609,000
Pretax Income TTM
$-77,611,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,208,000 | -77,611,000 | 780,556,000 | 10,070,000 | — | -36,988,000 |
| Dec 2024 | 0 | -39,996,000 | -36,144,000 | 152,132,000 | 6,311,000 | — | -29,234,000 |
| Dec 2023 | 0 | -31,668,000 | -31,632,000 | 94,642,000 | 4,211,000 | — | -29,837,000 |
| Dec 2022 | 0 | -12,821,000 | -12,648,000 | 44,273,000 | 2,772,000 | — | -11,458,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.94
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | $5.61B | $67.65 | — |
| COGT | Cogent Biosciences, Inc. | $5.80B | $33.94 | — |
| LEGN | Legend Biotech Corp | $5.48B | $29.53 | — |
| GRFS | Grifols SA | $5.45B | $8.01 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.03B | $98.90 | — |
News headlines (Yahoo Finance, 1h cache)
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses
2026-05-21 05:00 · Yahoo
Belite Bio Q1 Earnings Call Highlights
2026-05-20 22:06 · Yahoo
Belite Bio (BLTE) Q1 2026 Earnings Transcript
2026-05-20 21:59 · Yahoo
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE)
2026-05-20 10:57 · Yahoo
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-20 10:00 · Yahoo
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
2026-05-18 20:00 · Yahoo
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
2026-05-15 12:00 · Yahoo
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
2026-05-13 20:00 · Yahoo
Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA Submission
2026-05-03 06:08 · Yahoo
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1
2026-05-01 10:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.